Genetic Analysis AS announced ththat GA has entered a distribution and technology transfer agreement with Omnigene Medical Technologies Ltd. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test, a CE-marked standardized gut microbiome test as a service to the UEA market. Gut microbiome profiling is increasingly required in the field of precision medicine as a surrogate endpoint or exploratory biomarker in research. This is due both to the impact of the gut microbiome on health and pharmaceuticals that can affect the microbiota composition itself.